- The disease
- Acute graft-versus-host disease (aGvHD) is a life-threatening complication that can occur after a bone marrow or stem cell transplant, where immune cells from the donor attack the recipient's tissues. High-risk aGvHD is associated with poor outcomes and affects the skin, gut, and liver. Corticosteroids are the standard first-line treatment, but a substantial proportion of patients do not respond adequately (per Westin et al, Bone Marrow Transplant 2021). The condition carries FDA Orphan Drug designation for CYP-001 (per Cynata Therapeutics ASX disclosures).
- What the asset is trying to do
- CYP-001 consists of mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs) using Cynata's proprietary Cymerus manufacturing process. MSCs are cells with known anti-inflammatory properties; in this context they are thought to act by suppressing the donor immune cells (T-cells) that drive tissue damage and by reducing circulating inflammatory signalling proteins (cytokines) (per Cynata Therapeutics ASX disclosures). Unlike conventional donor-derived MSC products, the iPSC starting point allows repeated manufacture from a single cell line rather than requiring multiple individual donors, which is intended to improve batch-to-batch consistency (per Cynata Therapeutics ASX disclosures). The cells are designed as an off-the-shelf allogeneic (non-patient-specific) product.
- What the trial is measuring, and why it matters
- The Phase 2 trial (NCT05643638) is evaluating CYP-001 administered alongside corticosteroids in adults with high-risk aGvHD (per ClinicalTrials.gov NCT05643638). The trial is placebo-controlled, meaning one group receives CYP-001 plus corticosteroids and the other receives placebo plus corticosteroids, allowing a direct comparison of outcomes (per ClinicalTrials.gov NCT05643638). Primary and secondary endpoints are not fully detailed in the available registry data; typical endpoints in this disease setting include overall response rate and non-relapse mortality, though analysts should verify the specific registered endpoints directly (per ClinicalTrials.gov NCT05643638).
- Efficacy benchmarks in this setting
- The only FDA-approved MSC product in GvHD is remestemcel-L (Ryoncil, Mesoblast), which is approved for steroid-refractory aGvHD in paediatric patients (per Ryoncil US prescribing information, FDA approval December 2024). In the pivotal study supporting that approval, the overall response rate at day 28 was 70% in the remestemcel-L arm versus 45% in the control arm (per FDA Briefing Document, Oncologic Drugs Advisory Committee, March 2024). For adult first-line aGvHD treated with corticosteroids alone, overall response rates of approximately 40-60% have been reported in the literature, though these vary considerably by risk stratification and grading system used (per Westin et al, Bone Marrow Transplant 2021). Any efficacy figures reported for CYP-001 to date come from an earlier Phase 1 single-arm study (NCT02923375) in a different patient population (steroid-resistant aGvHD) and are not statistically comparable to the controlled Phase 2 data being generated, nor to the approved-product figures cited above.